Zobrazeno 1 - 10
of 115
pro vyhledávání: '"C, Varette"'
Autor:
J.-M. Vannetzel, J.-C. Darmon, Xavier Pivot, J.-L. Mouysset, Elsa Curtit, C. Varette, C. Furtos-Fanget, L. Mansi, Stéphanie Catala, D. Spaeth
Publikováno v:
The Breast. 32:S60-S61
Autor:
Jean-Marie Andrieu, J. M. Pavlovitch, V. Lucas, Jean-Marc Tourani, Eric Pujade-Lauraine, C. Varette, D. Larregain, D. Mayeur, E. Vuillemin, P. Grise, B. Dufour, E. Ecstein, C. Boaziz, M. Di Palma, S. Merran, M. Untereiner
Publikováno v:
Annals of Oncology. 7:525-528
Summary Background This multicenter phase II trial was conducted in order to evaluate the efficacy and toxicity of the subcutaneous route of administration of rIL-2 in the treatment of patients with metastatic renal cell carcinoma and to check whethe
Autor:
C. Louvet, M Kulik, B. Demuynck, C. Varette, K. Beerblock, A. de Gramont, F Destroys du Roure
Publikováno v:
La Revue de Médecine Interne. 15:48-51
Resume Une patiente de 58 ans a ete hospitalisee pour accident vasculaire cerebral associe a une coagulopathie de consommation. Le bilan etiologique de cette coagulopathie permit de mettre en evidence un adenocarcinome ovarien a cellules claires de s
Autor:
A. Pigne, Aimery de Gramont, Dominique Soubrane, Marcel Krulik, Loïc Marpeau, Thierry Guillot, C. Varette, Christophe Louvet, K. Beerblock, B. Demuynck
Publikováno v:
European Journal of Cancer. 29:1835-1838
60 patients with metastatic breast cancer were entered in a phase II study using folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide. 47 had measurable visceral metastases and 13 had exclusively bone meta
Autor:
Jean-Didier Grangé, C. Louvet, C. Varette, B. Demuynck, Marcel Krulik, K. Beerblock, A. de Gramont, D. Soubrane, E Navarro-Carola
Publikováno v:
La Revue de Médecine Interne. 14:821-824
We studied the levamisole toxic effects in adjuvant therapy for colorectal cancer. The therapy toxic effects on 127 patients were statistically more important in the levamisole-treated group compared to patients treated with folinic acid and 5-fluoro
Autor:
B. Lagadec, Jean Cady, Marcel Krulik, S. Delfau, B. Demuynck, D. Gallot, M. Malafosse, Alain Sezeur, C. Varette, Loïc Marpeau, A. Pigne, Christophe Louvet, Barrat J, Jean-Yves Couturier, Aimery de Gramont
Publikováno v:
European Journal of Cancer. 28:53-58
40 patients with advanced ovarian cancer were treated with immediate debulking followed by sequential cisplatin and doxorubicin every 4 weeks, followed by second-look laparotomy (SLL). Six courses were given when residual disease (RD) was under 2 cm.
Autor:
L. Campbell, Michael Millward, Paul R. Harnett, V. Ripoche, C. Varette, M. Friedlander, L. Kayitalire, Roland Bugat, David R. Bell, J.A. Moreno
Publikováno v:
Annals of Oncology. 9:1343-1345
Summary Background Most patients with advanced ovarian cancer will relapse following platinum-based combination chemotherapy and be considered for second-line treatment. Gemcitabine, a nucleoside analogue, is active against a range of solid tumors. T
Autor:
J M, Tourani, C, Jaillon-Abraham, V, Lucas, Y, Chrétien, D, Mayeur, M, Di Palma, C, Boaziz, P, Grise, C, Varette, J M, Pavlovitch, D, Larregain, E, Ecstein, M, Untereiner, J M, Andrieu
Publikováno v:
Bulletin du cancer. 84(4)
We report a french experience of subcutaneous administration of interleukin-2 in treatment of patients with metastatic renal cell carcinoma. Thirty-nine patients with metastatic renal cell carcinoma were included in the study. During the 10-week indu
Autor:
Eric Raymond, Marcel Krulik, A. de Gramont, Christophe Tournigand, N Le Bail, C. Louvet, S Moreau, J Vignoud, Thierry André, C. Varette
Publikováno v:
European journal of cancer (Oxford, England : 1990). 33(2)
Oxaliplatin has shown in vivo cytotoxic activity against colorectal cell lines. Preliminary studies suggest potentiation of fluorouracil (5-FU). To assess this issue, we performed a phase II study in pretreated patients with advanced colorectal cance
Autor:
A, de Gramont, A, Pigné, C, Louvet, A, Sezeur, L, Marpeau, J C, Vaillant, J, Cady, C, Varette, B, Demuynck, J Y, Couturier, B, Lagadec, J, Milliez, J, Barrat, M, Krulik
Publikováno v:
Annales de chirurgie. 51(10)
The main prognostic factor in advanced ovarian cancer is the volume of residual disease after the initial laparotomy. Early debulking surgery after several cycles of chemotherapy, before the emergence of resistant cell lines, could improve the progno